eigerbioadmin, Author at EigerBio

24 07, 2017

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

eigerbioadmin 2017-07-24T12:02:26+00:00

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PALO ALTO, Calif., July 24, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced completion of enrollment [...]

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection eigerbioadmin 2017-07-24T12:02:26+00:00

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals
Gallery
Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals

2017 Press Releases, All Press Releases, Eiger Corporate News

29 06, 2017

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals

eigerbioadmin 2017-06-30T18:22:25+00:00

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals PALO ALTO and SAN DIEGO, Calif., June 29, 2017, Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), announced today an agreement to sell to Theragene Pharmaceuticals, Inc., a private biotechnology company, a non-strategic asset, Mydicar® (rAAV1-SERCA2a). Financial terms of the agreement include a total upfront of $3.1 million in [...]

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals eigerbioadmin 2017-06-30T18:22:25+00:00

14 06, 2017

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors

eigerbioadmin 2017-06-14T16:56:31+00:00

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors - Company Prepares to Advance Orphan Disease Pipeline PALO ALTO, Calif., June 14, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, [...]

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors eigerbioadmin 2017-06-14T16:56:31+00:00

12 06, 2017

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego

eigerbioadmin 2017-06-12T14:46:00+00:00

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego - Novel Liquid Formulation of Subcutaneous Exendin 9-39 Highlighted PALO ALTO, Calif., June 12, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for [...]

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego eigerbioadmin 2017-06-12T14:46:00+00:00

6 06, 2017

Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients

eigerbioadmin 2017-06-06T13:20:42+00:00

Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients PALO ALTO, Calif., June 6, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced completion of enrollment of the Phase 2 multiple-ascending dose (MAD) study evaluating subcutaneous (SC) exendin [...]

Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients eigerbioadmin 2017-06-06T13:20:42+00:00

30 05, 2017

Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7^th

eigerbioadmin 2017-05-30T12:02:59+00:00

Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th PALO ALTO, Calif. – May 30, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at [...]

Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7^th eigerbioadmin 2017-05-30T12:02:59+00:00

17 05, 2017

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B₄ (LTB₄) Modulation in Experimental Lymphedema

eigerbioadmin 2017-05-17T13:43:24+00:00

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema - Data Supports Ongoing Phase 2 ULTRA Study of Ubenimex in Lymphedema PALO ALTO, Calif., May 17, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced publication in Science Translational Medicine (STM) the results of extensive preclinical studies of ubenimex in [...]

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B₄ (LTB₄) Modulation in Experimental Lymphedema eigerbioadmin 2017-05-17T13:43:24+00:00

15 05, 2017

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

eigerbioadmin 2017-05-15T14:39:47+00:00

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension - Phase 2 LIBERTY Data Expected First Quarter 2018 PALO ALTO, Calif., May 15, 2017 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of [...]

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension eigerbioadmin 2017-05-15T14:39:47+00:00

12 05, 2017

Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results

eigerbioadmin 2017-05-12T12:53:17+00:00

Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results — Five Phase 2 Programs in Four Orphan Indications Progressing — Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif., May 12, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the [...]

Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results eigerbioadmin 2017-05-12T12:53:17+00:00

8 05, 2017

Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago

eigerbioadmin 2017-05-15T14:42:05+00:00

Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago PALO ALTO, Calif., May 8, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced HDV/HBV co-infection prevalence data from an International Classification of Diseases (ICD) analysis presented at Digestive Disease Week (DDW) in [...]

Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago eigerbioadmin 2017-05-15T14:42:05+00:00

A BIOPHARMACEUTICAL COMPANY DEVELOPING A DIVERSE PORTFOLIO OF WELL-CHARACTERIZED DRUGS FOR ORPHAN DISEASES

EIGER BIOPHARMACEUTICALS

ABOUT EIGER

MANAGEMENT TEAM

BOARD OF DIRECTORS

SCIENTIFIC ADVISORS

CORPORATE PRESENTATION

CONTACT US

EIGER PIPELINE

Jefferies Healthcare Conference

Eiger presented a corporate overview and business update at the Jefferies 2017 Global Healthcare Conference at 11:00 am ET on Wednesday, June 7, 2017, in New York City. View Webcast

EIGER CELEBRATES

NEWS AND EVENTS

PRESS RELEASES

CALENDAR OF EVENTS

Jefferies Healthcare Conference

Eiger presented a corporate overview and business update at the Jefferies 2017 Global Healthcare Conference at 11:00 am ET on Wednesday, June 7, 2017, in New York City. View Webcast

INVESTOR NEWS & EVENTS

PRESS RELEASES

CALENDAR OF EVENTS

INVESTOR RELATIONS

INVESTOR HOME

STOCK INFORMATION

FINANCIAL INFORMATION

INVESTOR PRESENTATIONS

CORPORATE GOVERNANCE

SHAREHOLDER SERVICES

STOCK PRICE

Prevailing Over HDV

HEPATITIS DELTA (HDV)

ABOUT HDV

ABOUT SARASAR® (LONAFARNIB)

ABOUT PEGYLATED-INTERFERON-LAMBDA

SARASAR® (lonafarnib), PEGYLATED-INTERFERON LAMBDA & HDV RESOURCES

SARASAR® (lonafarnib) CLINICAL STUDIES

PEGYLATED-INTERFERON-LAMBDA CLINICAL STUDIES

PUBLICATIONS & PRESENTATIONS

PROFESSIONAL & PATIENT RESOURCES

Rising Above Post-bariatric Hypoglycemia

POST-BARIATRIC HYPOGLYCEMIA

ABOUT POST-BARIATRIC HYPOGLYCEMIA

ABOUT EXENDIN 9-39

GLP-1 RECEPTOR ANTAGONISM

EXENDIN 9-39 & POST-BARIATRIC HYPOGLYCEMIA RESOURCES

EXENDIN 9-39 CLINICAL STUDIES

PUBLICATIONS & PRESENTATIONS

PROFESSIONAL & PATIENT RESOURCES

Overcoming PAH

PULMONARY ARTERIAL HYPERTENSION

ABOUT PULMONARY ARTERIAL HYPERTENSION

ABOUT UBENIMEX

UBENIMEX & PULMONARY ARTERIAL HYPERTENSION RESOURCES

UBENIMEX CLINICAL STUDY

PUBLICATIONS AND PRESENTATIONS

PROFESSIONAL AND PATIENT RESOURCES

Conquering Lymphedema

LYMPHEDEMA

ABOUT LYMPHEDEMA

ABOUT UBENIMEX

UBENIMEX & LYMPHEDEMA RESOURCES

UBENIMEX CLINICAL STUDY

PUBLICATIONS AND PRESENTATIONS

PROFESSIONAL AND PATIENT RESOURCES

eigerbioadmin

About eigerbioadmin

Eiger presented a corporate overview and business update at the Jefferies 2017 Global Healthcare Conference at 11:00 am ET on Wednesday, June 7, 2017, in New York City.

View Webcast

Eiger presented a corporate overview and business update at the Jefferies 2017 Global Healthcare Conference at 11:00 am ET on Wednesday, June 7, 2017, in New York City.

View Webcast

SARASAR^® (lonafarnib) CLINICAL STUDIES